Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
1496510-51-0Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1WANIDIGFXJFFEL-SANMLTNESA-NRelacorilant is a first-in-class, selective glucocorticoid receptor antagonist. Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing agent. By competitively blocking the glucocorticoid receptor, relacorilant prevents cortisol from activating anti-apoptotic survival pathways, thereby restoring the efficacy of cytotoxic therapies in the context of resistant cancers. Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
In a healthy-volunteer study, relacorilant 500 mg (single dose) and 250 mg daily for 14 days was demonstrated to reverse all the effects of prednisone 25 mg. In a phase 1 study, RNA profiling after 15 days of treatment with relacorilant and nab-paclitaxel showed on-target suppression of GR-dependent genes - including PTGS2, CXCL8, PTGER4, and IDO1 - that correlated with response to relacorilant and nab-paclitaxel therapy. Relacorilant antagonizes the effects of co-administered glucocorticoids, and is therefore contraindicated in patients that require exogenous glucocorticoids for a life-threatening condition.
Relacorilant is a potent and selective modulator of the glucocorticoid receptor (GR), with an inhibition constant (Ki) for receptor binding of 0.15 nM, and no measurable binding to other steroid receptors. In ovarian carcinoma cell lines, GR activation leads to upregulation of glucocorticoid-regulated kinase 1 (SGK1) and map kinase phosphatase 1 (MKP1)/dual-specificity phosphatase 1 (DUSP1) genes. In this context, cortisol binding to the GR is immunosuppressive, decreasing the secretion of pro-inflammatory cytokines. The antagonism of GR by relacorilant may therefore indirectly activate the immune system, thereby enhancing the apoptosis and anti-tumor activity of co-administered paclitaxel.
Relacorilant is primarily metabolized by cytosolic reductases and CYP3A. An active metabolite, CORT125295, has functional activity approximately 5-fold lower than relacorilant and represents 75% of the parent AUC. Relacorilant is a strong CYP3A inhibitor and a weak CYP2C8 inducer, and both relacorilant and CORT125295 are inducers of CYP1A2 _in vitro_.
1496510-51-0DTXSID801099345CHEMBL4068611Following the third consecutive daily dose, relacorilant Cmax and AUC is 720 ng/mL and 5,686 ng*h/mL, respectively. The median Tmax is 2.5 hours. When co-administered with a low-fat meal, relacorilant Cmax increased 1.7-fold, AUC increased 2-fold, and Tmax was delayed by 0.5 hours. When co-administered with a high-fat meal, relacorilant Cmax was increased 1.9-fold, AUC increased 2.4-fold, and Tmax was delayed by 0.25 hours. In mice, the bioavailability of relacorilant was estimated at 20.5% after oral dosing.
After a single oral dose of radiolabeled relacorilant 250 mg to healthy participants, about 73% of the dose was recovered in feces (<1% as unchanged parent drug) and 17% was recovered in urine (<2% unchanged).
Relacorilant's apparent volume of distribution is 2490 L after a single 150 mg dose under fasted conditions.
Relacorilant's apparent total clearance is 52 L/h under fasted conditions.